Anomali Appoints Justin Coker as Vice President and General Manager of EMEA to Drive Growth Across Europe and the Middle East
Anomali, the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that multi-decade industry veteran Justin Coker has been named Vice President and General Manager of Europe and the Middle East (EMEA). Coker takes the region’s helm during a period of explosive demand for Anomali’s leading cybersecurity solutions, which are delivering unmatched ability in precision threat detection and comprehensive response that stops immediate and future breaches and attacks.
“Anomali is building a world-class leadership team as we continue on our phenomenal growth trajectory around the world. Justin brings a powerful combination of experience and skill to ensure that our public and private sector customers and partners receive the attention needed to build efficient, high-performance security infrastructures that stop advanced breaches and the attackers targeting their enterprises,” said Ahmed Rubaie, CEO, Anomali. “We are excited to welcome Justin to the company; his commitment to the organization and regional expertise makes him the perfect leader for the job.”
Coker has spent more than 20 years in senior sales management roles at leading enterprise cybersecurity companies. He joins Anomali from IronNet Cybersecurity, where, as VP of EMEA, he built out a sales team from the ground up on its journey to its recent IPO. Prior to then, he was VP of EMEA at Skybox Security, where he grew the business from a start-up to a team of 50, along the way winning a comprehensive list of EMEA's largest organizations as customers and creating strong alliances with many of the premier partner organizations across the region. Before that, while at Symantec, he led the United Kingdom’s and Ireland's retail banking and finance enterprise sales team for five years. He has held other successful IT sales positions at AXENT Technologies, Parametric Technology, and Fujitsu. Throughout his professional career, Coker has exceeded expectations at building and scaling successful sales teams and has remained enthusiastic about delivering business value to his clients and partners.
“I am excited to be joining Anomali at such a pivotal phase of growth and innovation. I look forward to driving our deeper portfolio adoption across EMEA through the development of existing and new markets, coupled with the continued expansion of our global channel and technology partner ecosystem,” said Coker. “Anomali’s go-to-market approach in EMEA is centered around our continued passion for creating strong partnerships with our global enterprise clients and helping them capitalize upon significant business value. I look forward to fulfilling our mission to strengthen customers’ security efficacy and efficiency, fueled by our intelligence-driven detection and response solutions and world-class customer-focused team.”
Coker and his team will be furthering access to the award-winning Anomali portfolio, which includes ThreatStream, our leading threat management platform, Lens, the industry’s only Natural Language Processing (NLP) product that identifies all threats and IOCs in any web content to operationalize them across security infrastructures, and Match, our advanced global attacker detection and response solution that quickly identifies and responds to threats in real-time by automatically correlating all security telemetry data against active threat intelligence.
Twitter:
https://twitter.com/Anomali
LinkedIn:
https://www.linkedin.com/company/anomali/
Blog:
https://www.anomali.com/blog
Detect LIVE Conference:
https://www.anomali.com/detect-live
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management and refined by artificial intelligence and machine learning, the Anomali platform delivers proprietary capabilities that correlate an extraordinary volume of telemetry from customer-deployed security solutions with the largest repository of global intelligence, empowering security operations teams to detect threats with precision, optimize response, achieve resiliency, and stop attackers and breaches. Our Cloud-first SaaS-based solutions easily integrate into existing security tech stacks and accommodate hybrid deployments. Founded in 2013, Anomali serves public and private sector organizations, ISACs, MSSPs, and Global 1000 customers worldwide in every major industry. Leading venture firms including Google Ventures, General Catalyst, and IVP back Anomali. Learn more at www.anomali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006153/en/
Contact information
Joe Franscella
news@anomali.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 08:00:00 EET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom